Table 2 Patient characteristics
Study | Age | Sex | Baseline severity of COPD | Duration of inhaled steroid use prior to entry into trial | Mean baseline FEV 1 | Mean baseline number of exacerbations in year preceding trial |
|---|---|---|---|---|---|---|
WISP 14 | > 40 | Male & female | Post-bronchodilator FEV1 < 80% predicted | Minimum 6 months, mean 8 years | Withdrawn group: 1.40 L Steroid group: 1.31 L (post-bronchodilator) | Withdrawn group: 1.86 Steroid group: 1.93 |
O'Brien et al 17 | 40-79 | Male | Details not provided | Details not provided | 1.61 L | Details not provided |
COPE 15 | 40-75 | Male & female | Pre-bronchodilator FEV1 25-80% predicted | 83% of patients had used for at least 6 months | Withdrawn group: 1.69 L Steroid group: 1.78 L (post-bronchodilator) | All patients: 1.3 |
COSMIC 16 | 40-75 | Male & female | Pre-bronchodilator FEV1 30-70% predicted | Details not provided | Withdrawn group: 49.0 Steroid group: 48.1 (pre-bronchodilator % predicted) | Details not provided, all patients had 2 or more requiring treatment |